Need professional-grade analysis? Visit stockanalysis.com
$1.39B
N/A
N/A
N/A
MoonLake Immunotherapeutics (MLTX) trades on United States in USD. The company is classified in the Healthcare sector under the Pharmaceutical Preparations industry. The stock currently trades at $17.22, down 6.11% from the previous close.
Over the past year, MLTX has traded between a low of $6.25 and a high of $61.99. The stock has lost 56.4% over this period. It is currently 72.2% below its 52-week high.
MoonLake Immunotherapeutics has a market capitalization of $1.39B.
MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland.
Side-by-side comparison against top Healthcare peers.